Therapeutics Provider Evusheld Webinar
DSHS will host a Therapeutics Provider Webinar focused on Evusheld on Friday, February 11, 2022, from 12:00-1:30pm Central Time.
DSHS subject matter experts will discuss Evusheld use, eligible patient populations, and reporting requirements, along with the process for registering to administer the product. Providers from UT Southwestern and Austin Public Health will also share how they have managed and administered Evusheld in their practices. All health care professionals and health care organizations that interact with immunocompromised patients are encouraged to register for the webinar (Webinar ID 977 3762 0693, Passcode 958998).
Veklury Available for Order for Hospital Outpatient Settings
This week, Gilead expanded access of Veklury (remdesivir) to include additional outpatient classes-of-trade. New facility types that can order Veklury are as follows:
- Infusion Centers or Sites (i.e., physician’s offices)
- Long Term Care sites
- Dialysis Care
- Clinics (capable of infusion)
- Acute/Urgent Care
Veklury is not under allocation by US HHS or Texas DSHS. Facilities may purchase it directly from the distributor by first completing the Veklury Non-Hospital Access Attestation Form. Please refer all questions about ordering to the distributor at C19Therapies@AmerisourceBergen.com.
For more information about Veklury, please review the DSHS 2/2 email, titled “Veklury (remdesivir) available for order from distributor” and access the following resources:
US HHS/ASPR National Office Call Sessions Scheduling Update
On Tuesdays from 1:00-1:45pm CT, US HHS / ASPR holds their National Office Call Sessions to discuss allocation, distribution, and administration of COVID-19 therapeutics. These calls, previously held on both Tuesdays and Thursdays, will now take place only on Tuesdays.
Please email COVID19Therapeutics@HHS.gov to request Zoom links for these calls.
Reminder: Evusheld Authorization & Allocation
Evusheld is a COVID-19 therapeutic authorized for patients with moderate to severe immune compromise and who may have an inadequate response to the COVID-19 vaccine because of certain medical conditions or medications, or those who may be unable to receive a vaccine because of a history of severe allergic reaction. It is administered intramuscularly and requires a one-hour monitoring period after administration.
Facilities eligible to receive allocations of Evusheld are those facilities where these patients receive their routine medical care for their immunocompromising conditions. Evusheld requires a prescription and is not a replacement for COVID-19 vaccination in persons from whom vaccination is recommended. It is not authorized for use in unvaccinated individuals for whom COVID-19 vaccination is recommended.
For more information on Evusheld, please review this NIH Statement on Evusheld for Pre-Exposure Prophylaxis. If you have questions about Evusheld allocation requests, please contact our therapeutics team by email at therapeutics@dshs.texas.gov or by phone at (833) 832-7068, option 0.
Reminder: Do Not Return BAM/ETE, REGEN-COV to Manufacturer
Although the FDA’s January 24th revision of the Emergency Use Authorizations (EUA) for BAM/ETE and REGEN-COV rendered these treatments no longer authorized for use, product return of BAM/ETE and REGEN-COV to the manufacturer is not recommended. Any returned product will be destroyed.
The COVID-19 environment remains dynamic, and these therapeutics products may prove to be effective against future variants. If possible, providers are encouraged to store these products following proper storage guidelines outlined in each product’s EUA. If you have storage concerns or challenges, consider transferring the product to another location/site within your region or health system.
Reminder: COVID-19 Therapeutics Allocation Request Timeline
The deadline for placing an allocation request in this cycle for COVID-19 therapeutics is Thursday at 5:00 p.m. Central Time.
Allocation considerations are based on weekly allocation cycles. A new allocation cycle begins every Friday. For your request to be considered for the upcoming cycle, it must be placed in VAOS no later than Thursday, February 10th, by 5:00 p.m. Central Time. Any requests received after Thursday at 5:00 p.m. will be considered for the following allocation cycle.
Please note that if you are not allotted any therapeutics in a given allocation cycle, you must submit another order request the following cycle; requests are not “carried over” from one week to the next.
Expert Tip: VAOS Accessibility Assistance
Providers experiencing issues accessing the Vaccine Allocation & Ordering System (VAOS) are encouraged to contact the Provider Support VacManagement team by phone at (833) 832-7068 (Option 2) or by email at COVID19VacMgmt@dshs.Texas.gov.
|
